Table 7 Evaluation of differences in prevalence of HPV infected breast cancer patients among different studies
From: Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins
Study | Year/Country | HPV+ patients | HPV+ controls | Most prevalent HPV |
|---|---|---|---|---|
Current study | 2017/Iran | 48.6% | 16.1% | HPV-18 (22.2%) |
Islam et al. | 2017/India | 63.9% | 9.5% | HPV-16 (69%) |
Salman et al. | 2017/UK | 42% | 17% | HPV-39 (20%) |
Fernandes et al. | 2015/ Venezuela | 41.6% | NA | HPV-51 (30.7%) |
Herrera-Goepfert et al. | 2013/Mexico | 40% | NA | HPV-16 (87.5%) |
Sigaroodi et al. | 2012/Iran | 25.9% | 2.4% | HPV-16 and 18 (both 25%) |
Khan et al. | 2008/Japan | 21% | NA | HPV-16 (92%) |
Yu et al. | 2000/China | 43.8% | NA | HPV-33 (43.8%) |